Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial

Alexa B. Kimball*, Kenneth B. Gordon, Richard G. Langley, Alan Menter, Elliot K. Chartash, Joaquin Valdes

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

200 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences